2023-509542-35-00CompletedPhase 1
Study of MK-4830 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4830-001)
Source: EU CTIS (euclinicaltrials.eu) · Last updated 25 Aug 2025
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 147 (actual)
- First submitted
- 19 Feb 2024
- Start date
- 2 Mar 2020
- Lead sponsor
- Merck Sharp & Dohme LLC
- Diseases
- Gastric and esophageal cancer, Glioblastoma, Lung cancer, Mesothelioma, Ovarian cancer, Pancreatic cancer
- EU CT number
- 2023-509542-35-00
- EudraCT number
- 2019-003164-53
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 147
- 8 sites in 4 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Sites (8)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Institut Catala D'oncologia | L'Hospitalet de Llobregat | Spain | Completed |
| Hospital Universitario HM Sanchinarro | Madrid | Spain | Completed |
| Centre Oscar Lambret | Lille | France | Completed |
| Assistance Publique Hopitaux de Paris | Paris | France | Completed |
| Centre Hospitalier Universitaire de Poitiers | Poitiers | France | Completed |
| Athens Medical Center S.A. | Thessaloniki | Greece | Completed |
| Uniwersyteckie Centrum Kliniczne | Gdansk | Poland | Completed |
| Narodowy Instytut Onkologii im Marii Sklodowskiej Curie Panstwowy Instytut Badawczy | Warsaw | Poland | Completed |
This page is information, not medical advice. Discuss any trial with your doctor.